NON-breast HER2+ Malignancies
1 clinical trials · Condition
◉ Watch NON-breast HER2+ Malignancies
| Record | Firm | Date |
|---|---|---|
| Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer (NCT03696771) | Novartis Pharmaceuticals | 2018-12-27 |
Track NON-breast HER2+ Malignancies automatically
Every clearance here is in the API, with alerts when new ones post.